Akorn Inc (AKRX) - Financial and Strategic SWOT Analysis Review

Date: March 28, 2017
Pages: 52
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A6601F69018EN
Leaflet:

Download PDF Leaflet

Akorn Inc (AKRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Akorn Inc (Akorn) is a pharmaceutical company which carries out the development, manufacturing and commercialization of generic and branded prescription pharmaceuticals and branded and over-the-counter consumer health products and animal health pharmaceuticals. The company offers the products in various dosage forms including oral liquids, otics, ophthalmics, injectables, topicals, inhalants, and nasal sprays. It also offers contract manufacturing services. Akorn offers these products and services to physicians, surgery centers, clinics, optometrists, hospitals, long-term care, wholesalers, retail pharmacies, group purchasing organizations and other pharmaceutical companies. It operates manufacturing facilities in India and the US. The company has presence in the US, Canada, Mauritius, Luxembourg, Switzerland and India. Akorn is headquartered in Lake Forest, Illinois, the US.

Akorn Inc Key Recent Developments

Mar 01,2017: Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance
Dec 12,2016: Akorn Announces Completion of FDA Re-inspection of Decatur Facility
Nov 03,2016: Akorn Provides Third Quarter 2016 Results
Aug 18,2016: Akorn Appoints Robert Monahan as Senior Vice President of Corporate Development
Aug 04,2016: Akorn Provides Second Quarter 2016 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Akorn Inc - Key Facts
Akorn Inc - Key Employees
Akorn Inc - Key Employee Biographies
Akorn Inc - Major Products and Services
Akorn Inc - History
Akorn Inc - Company Statement
Akorn Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Akorn Inc - Business Description
Akorn Inc - Corporate Strategy
Akorn Inc - SWOT Analysis
SWOT Analysis - Overview
Akorn Inc - Strengths
Akorn Inc - Weaknesses
Akorn Inc - Opportunities
Akorn Inc - Threats
Akorn Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Akorn Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 01, 2017: Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance
Dec 12, 2016: Akorn Announces Completion of FDA Re-inspection of Decatur Facility
Nov 03, 2016: Akorn Provides Third Quarter 2016 Results
Aug 18, 2016: Akorn Appoints Robert Monahan as Senior Vice President of Corporate Development
Aug 04, 2016: Akorn Provides Second Quarter 2016 Results
May 16, 2016: Akorn Provides First Quarter 2016 Results
May 10, 2016: Akorn Completes 2014 Financial Statement Restatement and Reports Audited 2015 and Restated 2014 Results
Mar 22, 2016: Akorn Provides Preliminary Unaudited Full Year 2015 Financial Results and Issues 2016 Financial Guidance
Mar 07, 2016: Akorn Receives Expected Additional Delinquency Notice From Nasdaq
Jan 21, 2016: Akorn Appoints Greg Lawless as Chief Human Resources Officer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Akorn Inc, Key Facts
Akorn Inc, Key Employees
Akorn Inc, Key Employee Biographies
Akorn Inc, Major Products and Services
Akorn Inc, History
Akorn Inc, Subsidiaries
Akorn Inc, Joint Venture
Akorn Inc, Key Competitors
Akorn Inc, Ratios based on current share price
Akorn Inc
Akorn Inc (Cont.1)
Akorn Inc, Interim Ratios
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Akorn Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Akorn Inc, Performance Chart (2012 - 2016)
Akorn Inc, Ratio Charts
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Akorn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Valeant Pharmaceuticals International Inc
Teva Pharmaceuticals Ltd
Pfizer Inc
Perrigo Company Plc
Novartis International AG
Johnson & Johnson
Hikma Pharmaceuticals Plc
Fresenius Kabi AG
Apotex Inc
Allergan Plc
Skip to top


Italy Orthobiologics Procedures Outlook to 2020 US$ 800.00 Mar, 2014 · 15 pages

Ask Your Question

Akorn Inc (AKRX) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: